The study presented is a comprehensive overview of commercial parenteral protein
formulations, approved by the European Medicines Agency (EMA), 1995–2018. The …

Protein pharmaceuticals have become a significant class of marketed drug products and are
expected to grow steadily over the next decade. Development of a commercial protein …

Fluid transport that is driven by gradients of pressure, gravity, or electro-magnetic potential is
well-known and studied in many fields. A subtler type of transport, called diffusiophoresis …

In the emerging field of phyto-nanotechnology, 30–200 nm plant-derived extracellular
vesicles (PDEVs) are now known to contain active biomolecules that mediate cell-to-cell …

A substantial body of evidence indicates cationic, arginine-rich peptides (CARPs) are
effective therapeutic compounds for a range of neurodegenerative pathologies, with …

Unacceptably high viscosity is observed in high protein concentration formulations due to
extremely large therapeutic dose of antibodies and volume restriction of subcutaneous route …

Finding excipients which mitigate protein self-association and aggregation is an important
task during formulation. Here, the effect of an equimolar mixture of l-Arg and l-Glu (Arg· Glu) …

Excipients are substances that are added to therapeutic products to improve stability,
bioavailability, and manufacturability. Undesirable protein–protein interactions (PPI) can …

Novel drug candidates are continuously being developed to combat the most life-
threatening diseases; however, many promising protein therapeutics are dropped from the …

Purpose To explain the effects of cationic amino acids and other co-solutes on the viscosity,
stability and protein-protein interactions (PPI) of highly concentrated (≥ 200 mg/ml) …